Login / Signup

Hereditary tyrosinaemia type 1 in the absence of succinylacetone: 4-oxo 6-hydroxyhepanoate (4OHHA), a putative diagnostic biomarker.

Preeya RehsiKarolina WitekErin EmmettRachel CarlingCharles TurnerNeil DaltonTim HutchinNedim HadzicAnil DhawanRoshni Vara
Published in: JIMD reports (2024)
Hereditary tyrosinemia type 1 (HT1) is a rare metabolic disease resulting in acute liver failure in early infancy, hypophosphataemic rickets, neurological crises, liver cirrhosis and risk of hepatocellular carcinoma later on in life. It is caused by the deficiency of the enzyme fumarylacetoacetate hydrolase which is involved in the terminal step of the catabolic pathway of tyrosine. Diagnosis is made through clinical suspicion supported by biochemical abnormalities that result from accumulation of upstream metabolites. Detection of succinylacetone (SA) in dried blood spot or urine remains pathognomonic, however it is not always detectable. Here we describe three cases of HT1 presenting with atypical biochemistry, where SA was not always detectable, highlighting the importance of an additional disease biomarker, 4-oxo-6-hydroxyheptanoate.
Keyphrases
  • liver failure
  • hepatitis b virus
  • intensive care unit
  • body mass index
  • replacement therapy
  • weight gain
  • respiratory failure
  • brain injury